Primary resistance occurs in ~60% of patients, robust predictive biomarkers are lacking (PD-L1 is rarely expressed and not predictive; tumor mutational burden has limited utility), cumulative immune-related and cytotoxic toxicities complicate management, and high costs restrict global access. The gene discussed is CD274; the disease is neoplasm.